Abstract

The agonist profiles for Ca++ elevations mediated by the human alpha-2 adrenoceptor subtypes alpha-2A,alpha-2B and alpha-2C were compared in the clones of Chinese hamster ovary cells expressing comparable numbers of receptors. No difference was seen between the different clones with respect to the maximum Ca++ mobilizations or the concentrations producing half-maximal stimulation in response to noradrenaline. Ca++ elevations were sensitive to phospholipase C inhibitor U-73122 (1-[6-([17β]-3-methoxyestra-1,3,5[10]-trien-17-yl)aminohexyl]-1H-pyrrole-2,5-dione) and pertussis toxin-pretreatment. Although noradrenaline was equally potent and active in all the clones, marked differences in the response to the other agonists were seen. UK14,304 (5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine) was a full agonist (when compared to noradrenaline) for alpha-2A and alpha-2C, d-medetomidine ([+]-[S]-[4-(1-[2,3-dimethylphenyl]ethyl)-1H-imidazole]HCl) was a full agonist for alpha-2B and alpha-2C and oxymetazoline (3-[(4,5-dihydro-1H-imidazol-2-yl-)methyl]-6-[1,1-dimethylethyl]-2,4-dimethylphenol HCl) was a full agonist only for alpha-2B receptors. Clonidine (2-[2,6-dichloroaniline]-2-imidazoline HCl) was a partial agonist in all the cases; almost no response to this ligand was obtained in the alpha-2B-expressing cells. When the Ca++ responses are compared to the previously published results on cAMP inhibition in Chinese hamster ovary cells, clonidine seems to be significantly less efficacious in elevating Ca++ than in decreasing cAMP.

Physiologically,alpha-2 adrenoceptors couple primarily to inhibitory responses. However, there has been a growing evidence of coupling to stimulatory responses such as platelet aggregation, smooth muscle contraction and secretion (reviewed in Ruffolo et al., 1993;Hieble et al., 1995). The inhibitory responses are usually manifested at the cellular level both in endogenous and heterologous expression systems as an inhibition of adenylyl cyclase or Ca++ channel activity through Gi/o-type G proteins (reviewed in Regan and Cotecchia, 1992). Coupling to both inhibitory Gi and stimulatory Gs proteins has been indicated in recombinant CHO cells expressing all the humanalpha-2 adrenoceptor subtypes (alpha-2A,alpha-2B, alpha-2C) (Fraser et al., 1989; Eason et al., 1992), S115 cells expressingalpha-2B (Jansson et al., 1994), JEG-3 cells expressing alpha-2A and alpha-2B (Pepperl and Regan, 1993) and Sf9 cells expressing mouse alpha-2B (Näsman et al., 1997); similar coupling to pertussis toxin-sensitive inhibition and -insensitive stimulation of Ca++ currents is implicated in recombinant PC-12 cells expressing rat alpha-2D (analogous to humanalpha-2A) and alpha-2B (Soini et al., 1997). In several studies, alpha-2 receptors have also been observed to couple to Ca++ elevation. In some instances this has been related to stimulation of cation channels (Aburtoet al., 1993; Lepretre and Mironneau, 1994; Musgrave and Seifert, 1995) but also a coupling to Ca++ mobilization from the intracellular stores has been shown for alpha-A/D receptors in HEL human erythroleukemia cells (Michel et al., 1989; Dorn et al., 1997), rat cerebral astrocytes (Enkvistet al., 1996) as well as in CHO and COS-7 cells (Dornet al., 1997). In HEL cells (Åkerman et al., 1996; Dorn et al., 1997) and in rat cerebral astrocytes (Enkvist et al., 1996) also inositol-1,4,5-trisphosphate (IP3) elevations in response to alpha-2 adrenergic stimulation have been recorded. Pertussis toxin-sensitivity of this response has lead to a suggestion that this response would be mediated by βγ-subunits from Gi/o-type G proteins. Recently, scavenging of βγ-subunits has been shown to inhibitalpha-2A-induced Ca++ elevation in COS-7 cells (Dorn et al., 1997).

The current evidence of coupling of alpha-2 adrenoceptors to Ca++ elevation is thus based on alpha-2A adrenoceptors in endogenous and heterologous expression systems. Therefore we have in this study aimed to characterize the possible Ca++ signals through the other human alpha-2 receptor subtypes. All three subtypes of alpha-2 adrenoceptors were for this purpose expressed separately in CHO cells at similar expression levels. As they were all shown to couple to Ca++ elevations, their basic agonist pharmacological profiles were characterized; although the pharmacology ofalpha-2 adrenoceptors with respect to cAMP inhibition has been documented in various expression systems, the corresponding pharmacology with respect to Ca++ is largely unknown (see above).

Media.

Ca++ measurements.

The fluorescent Ca++-indicator fura-2 was used to monitor changes in intracellular [Ca++] (Grynkiewicz et al., 1985). The cells were harvested using phosphate buffered saline containing 0.2 g/liter EDTA, spun down, and loaded at 37°C in MEM alpha supplemented with 0.02 g/liter bovine serum albumin, 1 mM probenecid and 4 μM fura-2 acetoxymethyl ester for 20 min. The cells were washed once with Ca++-free TBM and stored on ice as pellets (medium removed). The measurement of intracellular free calcium was carried out as follows: one pellet was resuspended in TBM supplemented with 1 mM probenecid at 37°C and placed in a stirred quartz microcuvette in a thermostated cell-holder within a fluorescence spectrophotometer. Fluorescence was monitored either with a Hitachi F-2000 or a Hitachi F-4000 fluorescence spectrophotometer at the wavelengths 340 nm (excitation), 505 nm (emission) or with a PTI QuantaMaster fluorescence spectrophotometer at the wavelengths 340/360/380 nm (excitation), 505 nm (emission). The experiments were calibrated using 60 μg/ml digitonin, which gives the maximum value of fluorescence (Fmax) and 10 mM EGTA, which gives the minimum value of fluorescence (Fmin). The free Ca++-concentration was calculated from the fluorescence at 340 nm, 505 nm (F) using the equation[Ca++]=(F−Fmin)/(Fmax−F)×224nMin which the extracellular fura-2 fluorescence is subtracted from the F values.

Data analysis.

Student’s two-tailed t test was used in all the calculations of the significance. For the results, mean ± S.E.M. is given unless specifically indicated. The nonlinear least square curve fitting was performed using SigmaPlot for Windows 4.00 (Jandel Scientific, Corte Madera, CA).

Results

Human alpha-2 adrenoceptor subtypes coupled to elevation of [Ca++]i when heterologously expressed in CHO cells (fig. 1). This signal consisted of both a rapid and transient elevation and a more sustained elevation as also has been shown in HEL cells that express endogenous alpha-2A adrenoceptors (Kukkonen et al., 1997). In wild-type (untransfected) CHO cells no Ca++ elevations were observed in response to adrenergic stimulation (fig. 2). To be able to perform pharmacological comparison of the different subtypes, clonesalpha-2A-E47, alpha-2B-6 andalpha-2C-L3 (Pohjanoksa et al., 1997) were chosen as they expressed the receptors at approximately similar levels (1.88 ± 0.40, 2.40 ± 0.65 and 2.04 ± 0.42 pmol/mg, respectively, Pohjanoksa et al., 1997). No significant differences were seen between different subtypes with respect to the basal Ca++ level or the maximum elevation induced by noradrenaline, although the maximum Ca++ elevation may be somewhat larger for alpha-2B (fig. 2).

The [Ca++]i level under unstimulated conditions (basal) and after stimulation with 10 μM noradrenaline. There is no significant difference between any basal value or between any stimulated value for the recombinant adrenoceptor-expressing CHO cells (alpha-2A,alpha-2B, alpha-2C). In the case of the wild-type (untransfected) CHO cells, noradrenaline did not induce any Ca++ elevation. Number of batches of cells where the determinations have been done is 6 to 15.

Ca++ elevations were sensitive to the phospholipase C inhibitor (Bleasdale et al., 1990) U-73122 (12 μM, 10 min) whereas the less active analogue U-73343 (12 μM, 10 min) was without an effect (fig. 3). The noncomplete block may reflect the affinity of U-73122 that could not be used in higher concentration due to its low solubility. Almost complete inhibition was also obtained by pertussis toxin pretreatment (100 ng/ml, 24 hr) for all the subtypes although a somewhat larger remaining signal could still be resolved in alpha-2B expressing cells (fig. 3). These results together suggest that the Ca++ response is due to phospholipase C-β activation by Gi/o. The minor signal remaining after the pertussis toxin-pretreatment may reflect a coupling of alpha-2 receptors to pertussis toxin-insensitive G proteins.

The agonist pharmacology of different alpha-2 subtypes was further characterized. Noradrenaline always appeared to be a strong agonist with a similar potency (EC50) for all the subtypes, whereas the response to the other agonists varied largely among the subtypes (table 1; fig.4). UK14,304 was a full agonist (as compared to noradrenaline) both for alpha-2A andalpha-2C receptors although it had a much lower potency foralpha-2C, whereas oxymetazoline was a full agonist (as compared to noradrenaline) only for alpha-2B (table 1; fig.4). d-Medetomidine had a similar potency for all the subtypes and it was an essentially full agonist (as compared to noradrenaline) for alpha-2B and alpha-2C (table1; fig. 4). Clonidine was never a full agonist and it displayed a particularly small response in alpha-2B-expressing cells (table 1; fig. 4). To control the recombinant alpha-2 adrenoceptor-specificity of the Ca++ responses, the agonist responses were also tested in the wild-type CHO cells. Noradrenaline, UK 14,304, d-medetomidine and clonidine were without an effect, whereas oxymetazoline slightly elevated [Ca++]i(Δ[Ca++]max = 7.4 ± 2.3 nM, number of batches of cells = 7). This Ca++ elevation is too small to cause any error in the agonist potency measurements in the recombinant CHO cells.

The dose-response curves for different agonists in all the alpha-2 adrenoceptor subtypes. The results are from at least three to four different batches of cells where the experiments were performed at least in triplicate.

Discussion

Our results show that all the human alpha-2 receptor subtypes couple to Ca++ elevation when heterologously expressed in CHO cells at comparable levels. Both the maximum response and the EC50 of noradrenaline, the physiological ligand, were similar in all the subtypes suggesting that there should not be any major physiological differences in the coupling of the differentalpha-2 subtypes to Ca++ elevations. The Ca++ response is suggested to be mainly due to phospholipase C-β activation by Gi/o with a minor contribution from pertussis toxin-insensitive G proteins.

In the case of agonists there were marked difference both with respect to maximum Ca++ elevations and EC50 values. UK14,304 was a full agonist for both alpha-2A andalpha-2C but it had a 10-fold higher potency foralpha-2A. This is clearly a reflection of the 10-fold higher binding affinity of UK14,304 for alpha-2A [Marjamäkiet al., 1993 (S115 cells)]. d-Medetomidine was a full agonist for alpha-2C but it also gave high responses with both alpha-2A and alpha-2B. Interestingly, it had the same potency for all the subtypes. Its EC50, which was around 3 nM, was the lowest among all the tested agonists for any subtype and the same as its determined binding affinity foralpha-2 adrenoceptors in CHO cells (Pohjanoksa et al., 1997). Oxymetazoline was a full agonist only foralpha-2B, but it had a low potency for this subtype. On the contrary, it was a weak partial agonist for alpha-2A but had a markedly higher potency. This difference in potency seems to be a reflection of its 100-fold higher binding affinity foralpha-2A than for alpha-2B [Bylund et al., 1988 (HT-29 cells and human platelets); Lomasney et al., 1990 (COS-7 cells); Marjamäki et al., 1993(S115 cells); Uhlen et al., 1994 (CHO cells)]. Clonidine was most active for alpha-2C but had a higher potency foralpha-2A; the latter may relate to its higher binding affinity for alpha-2A than for alpha-2C [Janssonet al., 1994 (S115 cells); Pohjanoksa et al., 1997 (CHO cells)]. Barely any signal could be observed inalpha-2B-expressing cells.

It has previously been shown that agonists differ in their ability to induce activation of Givs. Gsthrough alpha-2 receptors (Eason et al., 1994). Noradrenaline is a full agonist with respect to both Gi and Gs coupling (Eason et al., 1994), whereas imidazolines, like UK14,304, differ markedly in their ability to activate Gs (Eason et al., 1994). In our study, only a marginal Ca++ elevation remained after pertussis toxin-pretreatment. Therefore coupling to Gs is not a significant pathway for Ca++ elevation byalpha-2-adrenoceptors in CHO cells, in accordance with previous studies in alpha-2A-expressing HEL and CHO cells (Michel et al., 1989; Dorn et al., 1997) and cerebral astrocytes (Enkvist et al., 1996). Thus, Gi/o proteins are likely to be implicated in the transduction of both cAMP decreasing and Ca++ elevating responses in CHO cells. Pertussis toxin-sensitive cAMP decrease is thought to be caused by inhibition of adenylyl cyclase via αi whereas pertussis toxin-sensitive Ca++elevation may occur through stimulation of phospholipase C-β by βγ subunits from Gi/o (Lee et al., 1993;Smrcka and Sternweis, 1993; Wu et al., 1993). This also appears to be the mechanism of alpha-2A induced Ca++ elevation in COS-7 cells (Dorn et al., 1997).

It is of interest to compare the current Ca++ results and the previously published results on the coupling of thealpha-2 adrenoceptor subtypes to cAMP inhibition (Pohjanoksaet al., 1997) in the same CHO cell clones as in the present study (alpha-2A-E47, alpha-2B-6,alpha-2C-L3). When the responses to the three agonists, noradrenaline, d-medetomidine and clonidine are compared with respect to cAMP inhibition and Ca++ elevation, the results are largely similar in the alpha-2C expressing cells whereas marked differences are seen in the alpha-2A- andalpha-2B-expressing cells. First, d-medetomidine and clonidine seem to be full agonists with respect to cAMP inhibition—as compared to noradrenaline—in alpha-2A-E47 and alpha-2B-6, whereas clonidine is less efficacious (40 and 16% of noradrenaline signal for alpha-2A-E47 andalpha-2B-6, respectively) and evend-medetomidine is less efficacious than noradrenaline (60 ± 3%) with respect to Ca++ elevation inalpha-2A-E47. This could suggest there is a receptor reserve with respect to cAMP inhibition in alpha-2A- andalpha-2B-expressing CHO cells. However, what contradicts this is the fact that the EC50 value for noradrenaline is of the same magnitude or even lower in all the clones with respect to Ca++ elevation than to cAMP inhibition. When cAMP inhibition is examined in clones expressing lower numbers ofalpha-2A (alpha-2A-E30) and alpha-2B receptors (alpha-2B-10), the relative responses to clonidine are with both subtypes significantly higher in the cAMP inhibition assay (72 and 71%, respectively) as compared to Ca++elevation assay (40 and 16%, respectively) in our study (P < .01 for both). Therefore, it seems that the coupling of alpha-2A and alpha-2B adrenoceptors to cAMP inhibition and Ca++ elevation displays some agonist specific features at least with respect to the response to clonidine (as compared to noradrenaline).

Altogether, our results show that all three human alpha-2 adrenoceptor subtypes couple to Ca++ elevation in CHO cells in a similar manner. This seems to occur through pertussis toxin-sensitive activation of phospholipase C. Different agonists display characteristic subtype-specific differences in potency and activity.

(1990) Expansion of the alpha 2-adrenergic receptor family: cloning and characterization of a human alpha 2-adrenergic receptor subtype, the gene for which is located on chromosome 2.Proc Natl Acad Sci USA87:5094–5098.